National Drug Schedules

Including but not limited to Nafarelin acetate.

For veterinary use

including but not limited to naloxegol oxalate

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

Including but not limited to: Paromomycin sulfate (for veterinary use)

in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose

For human use

For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).

For veterinary use.

For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.

For human use.

Except for sublingual immediate release dosage forms.

When sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.*

Except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.

For human use.

For human use - except preparations for topical use on the skin.